Article

Many options exist for uveitis management in children

Posterior uveitis can be difficult to manage in children, but manage it you must, said Susan Lightman, MD, PhD, FRCP, FRCOphth, Department of Clinical Ophthalmology, Institute of Ophthalmology, University College, London.

Posterior uveitis can be difficult to manage in children, but manage it you must, said Susan Lightman, MD, PhD, FRCP,FRCOphth, Department of Clinical Ophthalmology, Institute of Ophthalmology, University College, London.

She suggested dividing these patients into two groups: those with unilateral disease who can be treated with periocular orintraocular steroids, and those with bilateral disease who will generally need steroids or immunosuppressive agents.

In children with vitritis or mild cystoid macular edema (CME), Dr. Lightman recommends periocular steroids. The peak effectof this therapy will occur around 6 weeks. The effects can last for more than 3 months, and the therapy can be repeated. Thedownside: it often requires general anesthesia to administer, and it can cause a rise in IOP.

For children with severe vitritis and CME with visual loss, Dr. Lightman advised stepping up the therapy to intraocularsteroids, being sure to monitor the IOP rise closely.

In bilateral or severe unilateral disease, oral steroids may be necessary to control the inflammation.

"Be aware that there are social side effects as well as systemic side effects," Dr. Lightman said. "Steroids can cause 'moonface' and hirsutism, and children can be cruel."

She recommended administering one-half the adult dose in persons aged less than 12 years, and using prednisone 2.5 mg/dayduring periods of growth.

If the inflammation remains unchecked even with high-dose steroids, it's time to consider second-line agents such asmethotrexate, cyclosporine, azathioprine, and mycophenolate.

"Whatever you do, you must control the inflammation," Dr. Lightman said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.